Nexeon MedSystems, a company focused on development of deep learning systems for implantable medical devices, is making a major investment in the Internet of Medical Things technology. It has licensed a portfolio of 86 patents from Siemens relating to the internet of things (IoT) which can be used in a wide variety of medical device applications, most notably in hospitals, nursing facilities, or patients homes.

Nexeon chairman and CEO Will Rosellini says: “The technology is astounding and has the potential to revolutionise the healthcare industry, give better treatment and diagnosis to patients, ensure productivity and communication within medical facilities, and can provide personalised, targeted medicine.

The Siemens portfolio’s subject matter is directed toward self-healing control networks for building automation systems in the hospital and the home. The patents relate to wireless mesh networks to use in the IoT and enable commissioning, application level security, simplified bridging, and end-on-end IP security.

Addressing unmet need

Rosellini continues: “Siemens is one of the most innovative firms in the world. Integrating its network innovation with our patient-specific solutions will substantially reduce the burden of chronic disease. By addressing this unmet need, we will create tremendous value in the form of better and faster care with fewer in-office visits required, easier access to more accurate patient information and decreased complications due to more precise therapy and better monitoring.”

Nexeon champions the proposition that the Internet of Medical Things is the future of healthcare. Rosellini tells Hospital Matters editor John Whelan in an exclusive interview: “Our goal is to have a system that can ‘learn’ an individual patient’s disease and then predict that individual’s therapeutic need such that we maximise ‘on’ time and have the highest and most consistent quality of life possible for the patient. “ Other aims are to eliminate undesired side effects and to expedite and facilitate the means by which this therapy is provided. In designing solutions Nexeon has collaborated with neurologists and as a result has worked towards features that reduce the time required to program devices while also incorporating solutions to the other issues these doctors face in delivering care to their patients.

Rosellini adds: “From the number of interviews the Nexeon team has completed with who we think will be our early adopters, we anticipate that the key technical features will include the system’s ability to detect, measure, and collect brain signals while simultaneously providing targeted DBS therapy that will have the biggest impact on how this therapy is currently delivered.
“The sensing technology is unique, and the simulation therapy is controlled via adjustable algorithm. Because we have the ability to stream data from the deep brain level, we predict that this data could then help confirm or deny trends associated with neurological disease development and progression.”

Bolstering best practice

Rosellini is clear about the benefits of Nexeon technology particular at a time when “the squeeze on resources” in healthcare is a global issue and not confined to, for example, the NHS in the UK. He says: “What I envisage for our technology is that we will bolster current best practices, we will eliminate waste and error, and we will create additional capacity in a novel, inexpensive way. With this, we hope we resolve that variable. So we are increasing access to care while maintaining the same quality, and we are doing it in an efficient manner. That is my goal. And I think that’s how we maximise therapeutic outcomes and patient quality of life.

Nexeon is focusing on a number of target markets for the next few years. Rosellini concludes. “Our mission is to automate as many optimised therapeutic outcomes as we can, so I am laser focused on the countries where we have the most knowledge as to how to go and be successful. On the other hand, we have recognised the value in distributors and indirect product sales units in various countries. Given the right environment, we are able to use the expertise of these local teams to distribute our device to the physicians who would benefit from and would like to use our technology.”